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a b s t r a c t
Background: The benefits of childhood vaccines are critically dependent on vaccination coverage. We
used a vaccine registry (as gold standard) in Kenya to quantify errors in routine coverage methods (sur-
veys and administrative reports), to estimate the magnitude of survivor bias, contrast coverage with
timeliness and use both measures to estimate population immunity.
Methods: Vaccination records of children in the Kilifi Health and Demographic Surveillance System
(KHDSS), Kenya were combined with births, deaths, migration and residence data from 2010 to 17.
Using inverse survival curves, we estimated up-to-date and age-appropriate vaccination coverage, calcu-
lated mean vaccination coverage in infancy as the area under the inverse survival curves, and estimated
the proportion of fully immunised children (FIC). Results were compared with published coverage esti-
mates. Risk factors for vaccination were assessed using Cox regression models.
Results: We analysed data for 49,090 infants and 48,025 children aged 12–23 months in 6 birth cohorts
and 6 cross-sectional surveys respectively, and found 2nd year of life surveys overestimated coverage by
2% compared to birth cohorts. Compared to mean coverage in infants, static coverage at 12 months was
exaggerated by 7–8% for third doses of oral polio, pentavalent (Penta3) and pneumococcal conjugate vac-
cines, and by 24% for the measles vaccine. Surveys and administrative coverage also underestimated the
proportion of the fully immunised child by 10–14%. For BCG, Penta3 and measles, timeliness was 23–44%
higher in children born in a health facility but 20–37% lower in those who first attended during vaccine
stock outs.
Conclusions: Standard coverage surveys in 12–23 month old children overestimate protection by ignoring
timeliness, and survivor and recall biases. Where delayed vaccination is common, up-to-date coverage
will give biased estimates of population immunity. Surveys and administrative methods also underesti-
mate FIC prevalence. Better measurement of coverage and more sophisticated analyses are required to
control vaccine preventable diseases.
 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Vaccines are the most powerful and cost effective interventions
in public health; they prevent 3 million childhood death annu-
ally, foster health equity and yield a US$44 return on investment
for every US$1 spent [1–3]. However, the impact of vaccination is
highly dependent on coverage [4]. Vaccine coverage estimates
are widely used as a metric of performance of vaccination
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programmes both nationally and globally [5–7]. The benchmark of
vaccination programme performance is coverage of the 3rd dose of
a vaccine containing diphtheria-tetanus-pertussis (DTP3) at 12
months of age [8].
Following introduction of the Expanded Program on Immuniza-
tion in 1974, global coverage of DTP3 rose to 21% by 1980. The
WHO programme ‘Universal Child Immunization by 1990’
advanced this to 75% in 1990 but it remained stagnant for a further
15 years. Following the drive by WHO, UNICEF, Gavi, The Vaccine
Alliance and other partners, global DTP3 coverage increased to
85% in 2015 but has stagnated again. In addition, 1-in-7 children
remain unvaccinated and considerable geographical variation in
coverage exists at both national and sub-national levels [9]. These
factors have driven a focus on equitable access to vaccines [6,10].
Ideally, coverage should be measured continuously using elec-
tronic immunisation registry that records vaccinations received
by all individuals in birth cohorts, or by the administrative method
(vaccine doses given) [5,11]. Electronic vaccine registries are not
routinely used in the low and middle income countries. So, the
two principal methods supporting national and global coverage
estimates are: administrative coverage and random cluster sur-
veys. Administrative coverage is calculated using aggregate
reported data (tallied from monthly reporting forms) on the num-
ber of vaccine doses administered to children in the target popula-
tion in a given period of time and target population estimates.
Because population denominators are, on average, 5 years out of
date these frequently produce estimates in excess of 100% [12–
15]. Demographic and Health Survey (DHS), Multiple Indicator
Cluster Survey (MICS) and EPI Cluster Surveys produce more reli-
able estimates because they are not dependent on census data
[16–18]. However, survey methods are susceptible to selection,
recall and coverage biases; for example, they fail to capture unreg-
istered, migrant populations [5,19].
Coverage is typically estimated for children aged 12–23 months
and referenced to their vaccination status at 12 months of age. This
focuses on survivors of infancy and, if vaccination is associated
with survival, there is scope for survivor bias. It also discards infor-
mation on timeliness of vaccination yet it is possible that timeli-
ness is a more sensitive indicator of health equity than a static
coverage percentage [20,21]. Finally, in a modern vaccine pro-
gramme with a wide range of antigens, focus on delivery of indi-
vidual vaccines does not take account of correlation between
coverage of different vaccines and estimates the proportion of chil-
dren who are fully immunised with difficulty.
Beyond being a performance metric, coverage is also a proxy
measure of population immunity with relevance to disease control.
Since coverage is closely related to disease incidence, monitoring
coverage can identify likely gaps in immunity before increases in
disease incidence are observed [22]. For diseases of infancy like
invasive infections caused by Streptococcus pneumoniae, coverage
at 12 months of age is a poor estimate of protection during infancy
and alternative measures, incorporating the timeliness of vaccina-
tion, are likely to be more useful.
Here we use a vaccine registry in Kenya [23] to quantify errors
in routine coverage methods, to estimate the magnitude of sur-
vivor bias, contrast coverage with timeliness and use both mea-
sures to estimate population immunity. Finally, we examine the
risk factors for delayed immunisation and illustrate the breadth
of inequality in both coverage and timeliness across different birth
cohorts and different locations.
2. Methods
The study is an analysis of all vaccinations recorded in an
electronic registry, established within the Kilifi Health and
Demographic Surveillance System (KHDSS) in Kenya, between
2010 and 2016.
2.1. Study setting and population
The KHDSS which is located on the Indian Ocean had a census in
2000 to define the resident population and following that, all sub-
sequent births, deaths and migration events are monitored by enu-
meration visits by fieldworkers to every participating household at
approximately 4-monthly intervals [24]. This population registry
has informed assessments of vaccine effectiveness and disease
incidence among children and older residents of the Kilifi County
area covered by the KHDSS [25–27].
The Kilifi Vaccine Monitoring Systemwas established in 2009 in
all 21 vaccine clinics in and around the KHDSS area. As the vaccine
service expanded, we incorporated a further 15 clinics between
2011 and 2016 [23]. As previously described, children who are res-
idents of KHDSS, attending clinics for vaccination, are matched
electronically to the KHDSS population register and all the vaccina-
tions they received are recorded at the clinic in real time. This also
provides an avenue for updating the KHDSS population register for
the new-borns [23,24]. Data are entered using laptop computers at
the vaccine clinics and are synchronised to a bespoke MySQL
v5.6.19 relational database at the main facility through weekly
hard-copy transfers on laptops. Data management procedures are
described elsewhere [23,24].
2.2. Statistical analysis
Demographic event data (births, deaths and migrations) were
combined with vaccination data from the vaccine clinics to create
individual life histories of a rolling cohort of children. The data
were analysed using survival analysis tools and presented as
inverse survival curves with age as analysis time. We focused on
two time points for estimating coverage: (a) Vaccine coverage, also
referred to as ‘Up-to-date vaccination coverage’ was defined as the
proportion of children vaccinated by their first birthday; (b) Age-
appropriate vaccination was defined as the proportion of children
vaccinated within 4 weeks of the age of vaccine eligibility in the
Kenya routine childhood immunisation schedule (see Table 1)
[28]. According to this programme, a Fully Immunized Child was
defined as one who had received a dose of Bacille Calmette-
Guérin vaccine (BCG), a 3-dose course of each of Pentavalent vac-
cine (targeting Diphtheria, Pertussis and Tetanus [DPT], Hepatitis
B and Haemophilus influenzae b), Oral Polio Vaccine (OPV) and
Pneumococcal Conjugate Vaccine (PCV), and a first dose of
measles-containing vaccine (MCV1) before his or her first birthday
[29].
We sampled the event data in different ways to simulate differ-
ent field approaches:
(i) Birth cohort analyses. For these analyses, the denominator
was the number of children who survived to the age of vac-
cine eligibility; the numerator was the number of these chil-
dren who were then vaccinated within four weeks (age
appropriate vaccination) or before their first birthday (vac-
cine coverage), regardless of whether they survived to these
age milestones.
(ii) Cross-sectional coverage surveys. We sampled the vaccine
coverage status of all resident children aged 12–23 months
on 1st July each year. Although we used a total population
sample, this still mimics the approach of a cluster sample
survey. To ensure the populations in the survey analyses
were linked to those in birth cohort analyses, we offset the
annual birth cohorts by six months (Fig. 1A); for example
the 2010–11 birth cohort consisted of all children born
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between 1st July of 2010 to 30th June of 2011 and the cross-
sectional survey of coverage of 12–23 month-olds, corre-
sponding to this cohort, was undertaken on 1st July 2012.
We estimated the median age at vaccination from inverse sur-
vival curves for each vaccination type. We estimated the timeliness
of vaccination as the proportion of all children vaccinated by the
age of 12 months who had received their vaccine within 4 weeks
of becoming age-eligible. As an indicator of population immunity,
we also estimated mean vaccine coverage among eligible infants
as the area under the inverse survival curves (AUC) for vaccination
between the age-eligible thresholds and 12 months of age (Fig. 1B)
[30]. Age-eligible thresholds for Penta 1, 2 and 3 were 6, 10 and 14
weeks, respectively. Similar thresholds were applied to OPV and
PCV. The threshold for MCV1 was 36 weeks. We also explored
health equity in timeliness and final coverage over time and place
by plotting inverse survival curves for BCG, Penta3 (DPT3) and
MCV1 for each birth cohort and in each of the 15 administrative
locations in KHDSS.
We used Cox regression models to estimate the risk factors for
vaccination. The risk factors examined were drawn from variables
available within the KHDSS, including place of birth, sex, birth
Table 1
The Kenyan childhood immunisation schedule.*
Vaccine Programme started Birth 6 wks 10 wks 14 wks 9 mths 18 mths
BCG 1
Oral Polio Vaccine (OPV) 0 1 2 3
Inactivated Polio Vaccine (IPV) Nov 2015 1
DPT-HepB-Hib (Pentavalent) Nov 2001 1 2 3
Pneumococcal vaccine (PCV10) Jan 2011 1 2 3
Rotavirus vaccine July 2014 1 2
Measles and Rubella (MR) June 2016 1 2
Fig. 1. A-B – Schema showing sampling of populations for estimating vaccination coverage and parameters for area under the curve measurements.
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order, maternal age and distance of the child’s home to the nearest
vaccine clinic. To understand the differences between population-
based and administrative coverage estimates we compared the
KHDSS survey estimates for the 12–23 month old survey popula-
tion in 2014 against the coverage estimates from Kilifi County in
the 2014 DHS survey [31] and routinely reported administrative
estimates from Kilifi County in 2014 (Kilifi County Reports). The
administrative estimates are obtained from monthly aggregates
of daily tally sheets filled out in each vaccine clinic and from
monthly review of the paper vaccine registers/books that are then
aggregated at the level of each sub-County within Kilifi before col-
lation to obtain overall County estimates.
All analyses presented here are confined to children born into,
and continuously resident in, the KHDSS. Coverage are presented
with 95% confidence intervals.
All statistical analyses were undertaken in Stata/ICTM 13.1 (Stata-
Corp, College Station, Texas, USA).
2.3. Ethics statement
This study was approved by the Kenya Medical Research Insti-
tute’s (KEMRI) Scientific and Ethics Review Unit (SSC 1433).
3. Results
In 6 birth cohorts (2010/11-2015/16), we studied 45 576 person
years of observation (pyo) among 49 090 infants. The 6 related
cross-sectional samples of children aged 12–23 months (2012–
2017) comprised a total study population of 48 025. The size of
each of the birth cohorts at each vaccination point in the childhood
schedule, taking account of losses due to mortality and migration,
is given in Fig. 2.
3.1. Vaccination coverage by birth cohort and survey
For each vaccine, coverage at age 12 months increased steadily
with each advancing birth cohort but then declined in 2015–16,
the last year (Table 2). The timeliness of vaccination also improved
over time and then declined, though the patterns were not as con-
sistent from vaccine to vaccine. The greatest disparity between
timely coverage (4 weeks after the child became age-eligible)
and vaccine coverage (at 12 months) was seen for measles vaccine,
which is also the vaccine that is scheduled closest to 12 months of
age. In the last 3 years of the study the estimates for coverage of
the Fully Immunised Child were within 1% of the coverage esti-
mates for measles, suggesting that the great majority of children
presenting for MCV1 are already up-to-date on all other vaccines.
The estimate of vaccine coverage derived from sampling chil-
dren aged 12–23 months was greater than that derived from the
birth cohort analysis in all birth cohorts and for all vaccines, except
for measles vaccine in the 2015–16 birth cohort where the two
coverage estimates were the same (77.5%, Table 2). The mean dif-
ference between survey and birth cohort coverage estimates at 12
months of age were 2.6%, 2.2%, 2.2%, 2.2%, 1.4% and 1.6% for BCG,
Penta3, OPV3, PCV3, MCV1 and the fully immunised child.
The patterns of coverage of other vaccine doses (OPV1, OPV2,
Penta1, Penta2, PCV1, PCV2) over time, and the disparity between
coverage estimation methods were similar (Supplementary
Table 1).
3.2. Comparing published coverage estimates
Vaccination coverage estimates, referenced to 2014, differed by
source (Table 3). KHDSS survey coverage estimates appeared
higher than coverage estimates for Kilifi County in the 2014 Kenya
DHS report for all vaccines except BCG. However, the confidence
intervals around the coverage estimates overlapped for all of the
vaccines. Compared to the KHDSS survey estimates, administrative
estimates for Kilifi County in 2014 were very similar for all vacci-
nes except for BCG, where the administrative coverage estimate
was 5% higher than the KHDSS survey estimate. Measures of the
proportion of children who were fully immunised were consider-
ably lower using both the DHS survey (71.5%) and the administra-
tive method (67.2%) than using the survey approach in the KHDSS
data (81.4%).
3.3. Timeliness of vaccination
The proportion of children vaccinated by 12 months of age who
had received the vaccine within 4 weeks of becoming eligible
(‘Timely vaccination’) is presented in Table 2 and Supplementary
Table 1. The proportion of vaccinated infants receiving a timely
vaccination increased over time for BCG, Penta3 and PCV3 but
declined for OPV3 and MCV1.
Predictably, the mean coverage among eligible infants i.e. the
area under the curve (AUC) was always lower than the final vac-
cine coverage at 12 months. The difference between these two esti-
mates was 1.1% for BCG, 7.9% for OPV3, 7.2% for PCV3 and Penta 3
and 24.2% for MCV1. These differences are reflected in the spread
of the inverse survival curves in Fig. 3.
Apart from 2010 to 11, which was the year of introduction of
PCV3, delivery of PCV3 and Penta3 was timely, as was BCG. How-
ever, there is marked variation in the timeliness of OPV3 by birth
cohort and timeliness of MCV1 is consistently poor across all birth
cohorts.
3.4. Inequality in timeliness and coverage by location
Variation in the inverse survival curves for vaccination with
BCG, Penta3 and MCV1 by administrative location is illustrated in
Fig. 4. The dispersion of the curves is greatest for MCV1 (Fig. 4E)
and least for BCG. For BCG, the AUCs varied from 86.3% to 93.8%;
for Penta3, AUCs varied from 68.1% to 88.7%; and for MCV1 AUCs
varied from 52.9% to 59.8%. Some inequality in timeliness of Penta3
vaccination is apparent in Fig. 4C and D. The take-off in the curve
for MCV1, indicating the first age at vaccination, varied from loca-
tion to location, with some locations starting at 33 weeks and
others not beginning until 36 weeks (Fig. 4E and F). In these fig-
ures, age-appropriate vaccination is estimated by the y-axis value
as each curve traverses the second vertical line (4 weeks after vac-
cination). These ranges are 68–82% (BCG), 58–78% (Penta3) and
19–49% (MCV1). ‘Up-to-date coverage’ at age 12 months varied
within the ranges 84–92% (BCG), 81–91% (Penta3) and 70–82%
(MCV1).
3.5. Predictors of coverage and timeliness
The univariate and multivariable hazard ratios for risk factors
for timely coverage are shown in Table 4. After accounting for
the secular trend in improved coverage (BCG and Penta3), the fac-
tors associated with more timely uptake are delivery in a health
facility and increasing birth order. Factors associated with delayed
coverage are vaccine stock outs, increasing maternal age and
increasing distance of the home from the vaccine clinic. The risk
and beneficial factors were broadly similar for the three vaccines
except that for measles maternal age and birth order were not
associated with vaccine timeliness and the impact of stock outs
was less remarkable. The results for PCV3 and OPV3 (Table S2)
reflect those of Penta3.
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4. Discussion
By studying an entire population sample in a Vaccine registry,
we have been able to characterise the accuracy of different meth-
ods and metrics of vaccination coverage in the setting of a vaccina-
tion programme in an LMIC. The principal findings of this analysis
are: (i) vaccination coverage estimates using a survey approach in
the second year of life overestimate coverage by approximately 2%;
(ii) compared to a total population survey in KHDSS, the cluster-
survey based DHS approach in 2014 underestimated coverage of
Penta3, OPV3 and PCV3 by 4–7% but the results for BCG and
MCV1 were equivalent in both methods; (iii) against the same
Fig. 2. Timeline and vaccination coverage experience for annual birth cohorts compared to survey samples of 12-23-month-olds.
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standard, the administrative methods overestimate BCG coverage
by 5% but were otherwise accurate; (iv) DHS and administrative
methods considerably underestimate the proportion of children
who are fully immunised by 10–14%; (v) the timeliness of vaccina-
tion in this population exhibited variation both in time and loca-
tion; (vi) Factors affecting coverage (‘risk factors’) were similar
for each of the antigens – the largest associations with failure to
vaccinate were a vaccine stock-out at the time of presentation
and birth of the child outside of a hospital; (vii) Survey estimates
of vaccination coverage are a poor guide to population immunity,
even though they are frequently used to populate models of vac-
cine impact; for all vaccines except BCG, the AUC was substantially
lower (7–24%) than the survey coverage.
Overall, coverage for most vaccines in Kilifi is good and has been
improving throughout 2011–2016, a period of rapid introduction
of new vaccines (PCV, Rotavirus, Inactivated Polio Vaccine and
Table 2
Vaccination coverage, timeliness of vaccination and the Fully Immunised Child among residents of the Kilifi Health and Demographic Surveillance System (KHDSS) by birth cohort
and survey population aged 12–23 months.
Vaccine Cohort Coverage birth cohort
(95% CI)
Median
age (weeks)
Timely
vaccination (%)*
AUC**
(%)
Year Coverage 12–23 months
(95% CI)
Median age
(weeks)
Timely
vaccination (%)*
BCG
2010–11 88.7 (88.1–89.4) 2.6 62.3 86.3 2012 91.0 (90.4–91.7) 2.6 63.9
2011–12 88.5 (87.8–89.2) 2.1 68.4 86.9 2013 91.2 (90.5–91.9) 2.1 71.0
2012–13 89.8 (89.1–90.5) 1.9 75.1 88.7 2014 93.4 (92.8–93.9) 1.7 78.8
2013–14 92.6 (92.0–93.2) 1.0 85.8 92.1 2015 96.2 (95.7–96.6) 1.0 89.5
2014–15 94.2 (93.7–94.7) 0.6 87.4 93.8 2016 96.0 (95.6–96.5) 0.6 89.4
2015–16 89.0 (88.3–89.7) 0.9 77.8 88.3 2017 90.5 (89.8–91.2) 0.9 79.3
OPV3
2010–11 87.5 (86.8–88.2) 15.7 70.5 81.4 2012 89.6 (88.9–90.3) 15.5 72.2
2011–12 87.6 (86.8–88.3) 15.4 72.3 82.0 2013 89.9 (89.2–90.6) 15.4 74.4
2012–13 88.2 (87.5–89.0) 15.8 65.2 80.7 2014 91.4 (90.7–92.0) 15.7 68.1
2013–14 91.6 (90.9–92.2) 15.2 77.3 86.2 2015 94.5 (93.9–95.0) 15.2 80.1
2014–15 90.8 (90.1–91.4) 16.5 55.8 78.9 2016 92.1 (91.4–92.7) 16.4 56.9
2015–16 85.9 (85.1–86.7) 18.2 49.1 74.8 2017 87.0 (86.1–87.8) 17.9 50.2
Penta3
2010–11 85.1 (84.4–85.9) 20.5 35.0 68.1 2012 86.8 (86.0–87.5) 20.4 35.6
2011–12 87.7 (86.9–88.4) 15.5 68.0 81.2 2013 89.8 (89.2–90.6) 15.5 69.8
2012–13 88.5 (87.8–89.2) 15.7 67.2 81.6 2014 91.7 (91.1–92.4) 15.5 70.2
2013–14 91.7 (91.1–92.3) 15.2 78.1 86.6 2015 94.6 (94.1–95.1) 15.2 80.8
2014–15 93.0 (92.4–93.6) 14.9 82.9 88.7 2016 94.6 (94.1–95.1) 14.9 84.8
2015–16 87.2 (86.5–88.0) 14.9 80.3 83.8 2017 88.6 (87.8–89.4) 14.9 81.8
PCV3
2010–11 84.0 (83.2–84.8) 20.9 41.1 66.0 2012 85.5 (84.7–86.3) 20.2 42.3
2011–12 87.5 (86.7–88.2) 15.4 74.2 82.4 2013 89.8 (89.1–90.5) 15.2 76.2
2012–13 88.2 (87.5–88.9) 15.7 67.0 81.2 2014 91.5 (90.8–92.1) 15.5 70.0
2013–14 91.6 (91.0–92.2) 15.2 77.6 86.4 2015 94.5 (94.0–95.1) 15.2 80.4
2014–15 92.9 (92.3–93.5) 14.9 82.4 88.6 2016 94.6 (94.0–95.1) 14.9 84.4
2015–16 87.3 (86.5–88.0) 14.9 79.4 83.7 2017 88.6 (87.8–89.4) 14.9 80.9
Measles
2010–11 79.4 (78.5–80.3) 41.1 39.6 57.9 2012 80.6 (79.7–81.5) 41.0 39.8
2011–12 78.2 (77.3–79.2) 41.7 33.5 53.8 2013 79.8 (78.8–80.7) 41.6 34.1
2012–13 81.7 (80.8–82.5) 41.4 36.4 57.8 2014 84.0 (83.2–84.9) 41.0 37.4
2013–14 84.7 (83.9–85.5) 40.9 36.4 59.8 2015 87.1 (86.3–87.9) 40.7 37.3
2014–15 83.8 (83.0–84.7) 41.1 31.0 57.7 2016 84.8 (83.9–85.7) 41.1 31.3
2015–16 77.5 (76.6–78.5) 41.6 27.8 52.9 2017 77.5 (76.5–78.6) 41.6 27.8
FIC 2011 71.7 (70.7–72.8) – –
2010–11 71.5 (70.6–72.5) – – – 2012 73.1 (72.1–74.1) – –
2011–12 74.2 (73.3–75.2) – – – 2013 76.2 (75.1–77.2) – –
2012–13 78.9 (77.9–79.8) – – – 2014 81.4 (80.4–82.3) – –
2013–14 84.0 (83.2–84.8) – – – 2015 86.4 (85.6–87.2) – –
2014–15 82.8 (81.9–83.6) – – – 2016 83.7 (82.8–84.6) – –
2015–16 76.8 (75.8–77.8) – – – 2017 76.8 (75.8–77.8) – –
BCG Bacille Calmette-Guérin vaccine (BCG), OPV3 Oral Polio Vaccine 3rd dose, Pentavalent Vaccine 3rd dose (Diphtheria, Pertussis, Tetanus, Haemophilus influenzae b and
Hepatitis B combination vaccine), PCV 3 Pneumococcal Conjugate Vaccine 3rd dose, MCV1 Measles-Containing Vaccine 1st dose.
* Proportion of vaccinated children who received their vaccines within 4 weeks of become age-eligible for vaccination.
** AUC % Area Under the Curve (see Fig. 1B).
Table 3
Comparison between ‘up-to-date vaccination coverage’ estimates in Kilifi and those from other sources.
Vaccine KHDSS survey
(12–23 months) 2014
Kilifi County
DHS 2014 [28]
Kilifi County DHS –
KHDSS survey
Kilifi County Administrative 2014* Kilifi County Administrative –
KHDSS survey
BCG 93.4 (92.8–93.9) 94.3 (89.3–97.6) 0.9 98.4 (98.2–98.6) 5.0
OPV3 91.4 (90.7–92.0) 84.7 (77.8–90.2) 6.7 92.6 (92.2–93.0) 1.2
Penta3 91.7 (91.1–92.4) 87.5 (81.0–92.4) 4.2 91.4 (90.9–91.8) 0.3
PCV3 91.5 (90.8–92.1) 87.4 (81.0–92.4) 4.1 91.9 (91.4–92.3) 0.4
MCV1 84.0 (83.2–84.9) 83.7 (76.2–89.0) 0.3 84.0 (83.4–84.6) 0
FIC* 81.4 (80.4–82.3) 71.5 (63.4–78.7) 9.9 67.2 (66.4–76.9) 14.2
* Obtained from routine immunisation reports by Kilifi County Department of Health, Kilifi, Kenya.
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the combined Measles-Rubella vaccine). Samples of our registry
that mimic widely utilized household surveys (MICS or DHS) tend
to overestimate coverage by approximately 2%. This is inevitable if
infant survival is associated with the probability of being vacci-
nated – either as a function of vaccine protection or as a manifes-
tation of the ‘healthy vaccinee’ effect [32]. The infant mortality
ratio is low in KHDSS (20/1000 live births in 2016); so the scope
for survivor bias is much greater in settings with high infant mor-
tality. Given the association between survival [33] and vaccination
coverage, inferences based on coverage estimates from surveys of
children in the second year of life should be made with more
caution.
Compared against our total population survey, coverage esti-
mates from the DHS were relatively accurate for BCG and MCV1,
the first and last vaccines of the programme but under-
estimated coverage of Penta, PCV and OPV by 4–7%. DHS instru-
ments rely on evaluation of vaccine cards and if these are missing,
on the recall of the parents. The first and last immunisations are
probably easier to recall. In addition, the DHS sampled 144 indi-
viduals in Kilifi in 2014, whereas the vaccine registry monitored
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Fig. 3. Age-specific vaccination coverage (inverse Kaplan–Meier estimates) in childhood residents of the Kilifi Health and Demographic Surveillance System by birth cohort.
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Fig. 4. Age-specific vaccination coverage (inverse Kaplan–Meier estimates) in childhood residents of the Kilifi Health and Demographic Surveillance System by birth cohort
and location.
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6790 children in that year so it is possible this disparity is the con-
sequence of a sampling error. Available evidence from household
coverage surveys show estimates based on recall alone exaggerate
coverage, combined/mixed vaccine card and recall result in large
errors in coverage estimates that trend in all directions while
restricting coverage estimates to data from cards alone signifi-
cantly underestimates coverage [34]. Despite the reliance on cov-
erage estimates from household coverage surveys by national and
global actors in the childhood immunisation field, it would appear
the results should be interpreted with an abundance of caution
[34].
Both sampling methods fail to identify mobile, transitory or
unregistered populations: in our analysis we excluded children
migrating into the area because we did not have a verifiable record
of their prior vaccination history. Population movements are asso-
ciated with vaccination coverage [35], and it is likely that survey
methods overestimate vaccination coverage by failing to sample
transitory sub-populations. Unfortunately, we could not quantify
the impact of migration on coverage estimates.
The 2014 administrative coverage estimates were remarkably
close to the survey estimates, except for BCG. The positive impres-
sion this gives of administrative methods must be tempered by the
fact that the ranges for administrative coverage in individual vac-
cine clinics in Kilifi were 20–384%, 52–144%, 52–145% and 51–
144% for BCG, OPV3, Penta3 and PCV3, respectively. It may be that
simple models of population growth have made accurate predic-
tions in this area as a whole, but that parents do not always take
their children to the nearest clinic; or it may be that the adminis-
trative methods were fortuitously accurate in this relatively simple
1-year comparison.
Our study shows that the prevalence of FIC is considerably
underestimated by DHS-type survey methods and is grossly under-
estimated by administrative methods. The similarity between the
coverage for MCV1 and FIC may be attributable to clinic staff fol-
lowing extant policy and using any vaccine visit to catch-up on
missed vaccinations. Immunisation program managers and others
like Gavi have advanced the FIC as a better measure of programme
performance at national level than single antigen metrics like DTP3
or MCV1, and this is now the hallmark analysis for equity of access
to vaccines [29,36]. If the FIC which is better aligned with the full
benefits of vaccination is to be adopted as a performance indicator,
then we will need new or improved monitoring systems that are
capable of linking the identity of the child across multiple records
of vaccines given. Although this is theoretically possible in vaccina-
tion cards and in clinic log books, as these vaccine registry results
show, it is more effectively accomplished electronically.
The inverse Kaplan Meier analyses were useful in assessing
uptake and timeliness of vaccination [30,37]. Many studies have
shown marked differences in age-appropriate and ‘up-to-date cov-
erage’ by socioeconomic status [38,39]. In this relatively homoge-
nous study setting, we also find significant location-specific and
year-to-year variation in timeliness. Essentially, this means unless
coverage is very high (>95%), it is very likely that the district or
national coverage figures will conceal significant local variation.
And as seen with MCV1, this becomes more relevant the later in
life a vaccine is given. This could lead to substantial islands of spa-
tiotemporal susceptibility which may ignite as, for example, unex-
pected measles outbreaks.
Factors associated with high coverage were younger maternal
age, more previous children, and delivery in hospital. The strongest
detrimental effect was vaccine stock outs, an operational challenge
that immunisation programmes should be able to tackle. Place of
birth and clinic visits post-delivery have been reported by us and
others as important for vaccination [40,41]. Increased contact with
healthcare services is believed to increase the likelihood of vacci-
nation via an intermediate step of health education. An alternative
explanation may be differential health-seeking behaviour related
to ‘healthy vaccinee’ bias. If this is true, interventions to improve
vaccination coverage by increasing deliveries at health facilities
may only benefit those already likely accept vaccines. Socio-
economic factors also contribute to inequities in coverage and time
to vaccination [38,39]. though these are hard to characterise reli-
ably in a relatively homogenous rural population.
In any setting with delays in vaccination, ‘up-to-date coverage’
will be a biased measure of vaccination-induced population immu-
nity [42] and this bias, always over-estimating protection, can be
as great as 24% in our survey [42–44]. AUC is a better measure
because it provides an estimate of mean vaccination coverage
throughout the period of risk. However, true population immunity
will be lower than the AUC because a small proportion of vacci-
nated children will not develop an appropriate antibody response
either because of operational factors (ineffective administration,
inactive vaccine, heat destroyed vaccine, etc.) or host factors
(immunodeficiencies) and even those who do respond adequately
Table 4
Predictors of up-to-date and age-appropriate vaccination among children in the KHDSS by birth cohort.
Univariate analyses Multivariable analyses**
BCG Penta 3 MCV1 BCG Penta 3 MCV1
Risk factors HR* 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI
Time trend (years) 1.12 1.11–1.13 1.14 1.13–1.15 0.99 0.98–1.00 1.13 1.12–1.14 1.14 1.13–1.15
Male sex 0.99 0.97–1.01 1.00 0.98–1.02 0.99 0.98–1.01
Maternal age (years)
<25 – – – – –
25–34 1.04 1.02–1.06 1.02 1.00–1.04 1.01 0.99–1.03 0.95 0.93–0.98 0.98 0.96–1.01
35 1.07 1.05–1.10 1.00 0.97–1.02 0.98 0.95–1.01 0.95 0.92–0.99 0.95 0.92–0.98
Place of birth
Home – – – – – –
Health facility 1.52 1.49–1.55 1.39 1.36–1.41 1.22 1.20–1.25 1.44 1.41–1.47 1.25 1.22–1.28 1.23 1.20–1.25
Distance from clinic
<3 km – – – – – –
3 km 0.93 0.91–0.95 0.96 0.94–0.98 0.95 0.93–0.96 0.96 0.94–0.98 0.96 0.96–1.00 0.96 0.94–0.98
Vaccine stock out 0.60 0.58–0.62 0.56 0.54–0.60 0.78 0.72–0.84 0.63 0.61–0.66 0.72 0.68–0.76 0.80 0.74–0.87
Birth order
<2 – – – – – –
2–5 1.09 1.07–1.11 1.02 1.00–1.03 1.02 1.00–1.04 1.25 1.22–1.29 1.12 1.09–1.14 1.04 1.01–1.07
>5 1.10 1.07–1.12 0.99 0.96–1.01 0.95 0.92–0.97 1.31 1.27–1.35 1.10 1.07–1.14 0.96 0.93–1.00
* HR, Hazard ratios indicate the increased ‘hazard’ of being vaccinated among each of the risk factor categories, compared to baseline.
** Adjusted for all other variables-year of birth, sex, maternal age, place of birth, distance from clinic, stockout and birth order.
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will not become immune until 2 weeks after a primary vaccine or 1
week after a booster. Seroepidemiological surveys provide more
accurate estimates of the population fraction protected by vaccina-
tion. They can identify at-risk groups via population immunity pro-
files and help inform strategies to increase or sustain population
immunity such as revisions of the vaccination schedule or mass
campaigns [45]. Whilst the AUC may be the best epidemiological
approximation of population immunity, more reliable estimates
of the vaccine induced immunity can only be obtained with sero-
logical surveys.
In LMICs, vaccines account for a rapidly increasing fraction of
health expenditure. Vaccine programmes are expensive but highly
effective, yet their impact is critically dependent on vaccination
coverage. This analysis of vaccine registry data, in a setting typical
of much of sub-Saharan Africa, illustrates that methods and mea-
sures for estimating coverage are suboptimal; biased by survival
to sampling date and by recall of vaccinations, incapable of reveal-
ing small area heterogeneity, unlinked and therefore unable to
estimate the prevalence of the Fully Immunised Child, blind to
the timeliness of vaccination and therefore to signal the gaps this
produces in population immunity. Our study can be replicated
across the LMICs in Africa and as part of the Comprehensive Health
and Epidemiological Surveillance System (CHESS) proposed by the
INDEPTH network [46].
The methodology of measuring vaccination coverage needs to
be improved on and with modern electronic record systems and
serological sampling, we have the opportunity to refine our tools
and make better use of the tremendous power of vaccination.
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